While the Democratic Republic of Congo has been witnessing an outbreak of the deadly Ebola disease, the country has agreed with the World Health Organisation to use an experimental Ebola vaccine.
Developed by the Canadian government and licensed to the U.S.-based Merck, the vaccine was tested in 2015 during an outbreak that killed more than 11,300 people in Guinea, Sierra Leone and Liberia.
Although it was developed for a different strain of virus than one that caused the 39 suspected, probable and confirmed cases of Ebola since April in the country, it is thought to be effective against the virus.
The disease has caused 19 deaths so far. The use of the vaccine would begin by the end of this week.